Founded in 1989, OrbiMed is a New York-based healthcare-dedicated investment firm managing approximately $5 billion in assets. It invests across the spectrum of healthcare companies, from private start-ups to large multinational corporations, focusing on biopharmaceuticals, life sciences, digital health, medical devices, and diagnostics sectors globally.

Founded in Boston in 2004, RA Capital is an investment firm specializing in life sciences and drug development. Its team, with backgrounds in biology, chemistry, medicine, and industry experience, invests in early-stage companies with promising technologies and products across healthcare and life science sectors.

Eli Lilly and Company is a global pharmaceutical leader engaged in the discovery, development, manufacture, and sale of medicines. It operates facilities in the United States, Puerto Rico, and many other countries, with products sold in about 135 countries. The company focuses on therapies in neuroscience, cardiometabolic, cancer, and immunology, and also conducts research in animal health and animal agriculture. Lilly supports patient outcomes and education through a philanthropic foundation that funds programs in underserved communities, including STEM education in Indianapolis.

Novo Holdings is a Danish holding and investment firm managing the assets of the Novo Nordisk Foundation. Established in 1999, it invests globally in life science companies at all stages of development, with a portfolio also including equities, bonds, real estate, and infrastructure.

Qiming Venture Partners is a China-based venture capital firm founded in 2006, with offices in Shanghai, Beijing, Suzhou, Hong Kong and Singapore, and a global arm through Qiming Venture Partners USA. It manages multiple funds and invests in early and growth-stage companies across technology, information technology, healthcare, new consumer sectors, AI, robotics, semiconductors, software and digital health. The firm emphasizes a hands-on approach, often taking board seats and providing operational guidance to help CEOs scale and reach exits. Through its investments, it has backed hundreds of companies and supported numerous IPOs and M&A outcomes, with unicorns among its portfolio, illustrating breadth and depth across China and international markets.

Established in 2020, the European Innovation Council supports innovative startups and researchers with promising ideas, focusing on early-stage companies with positive environmental, social, or governance impacts. It co-invests alongside private investors.

New Enterprise Associates is a venture capital firm founded in 1977 and based in Menlo Park, California, with offices in the United States, India and China. It makes investments across technology and healthcare startups at multiple stages, from seed to growth, including software, cloud, data, internet services, fintech, AI, e-commerce, and enterprise technology, as well as healthcare information technology, life sciences, medical devices, and biopharma. It also considers energy technology and infrastructure opportunities, such as solar, batteries and smart grids. The firm pursues a global approach, with activity in the United States, Asia and other regions, and supports companies through rounds of financing ranging from small to sizable investments as they scale. NEA focuses on building portfolios in software, IT services, consumer technology, and healthcare technology, backing ambitious entrepreneurs across sectors and geographies.

Samsara BioCapital is a venture capital firm based in Palo Alto, California, that focuses on biotechnology and life sciences companies in the United States. The firm seeks to invest in pharmaceutical and biotechnology ventures, including oncology and other healthcare technologies, with a goal of supporting entrepreneurs in turning ideas into developed therapies. It emphasizes collaboration with ambitious partners and aims to advance biotech innovation and important new therapies by providing capital and advisory support. The organization also operates as a registered investment adviser, offering investment advisory services to guide portfolio companies through growth and development.

Founded in 1986, Morningside Group is a venture capital firm based in the greater Boston area. It invests in companies with innovative science and technology across life sciences, digital health, AI, materials, and technology sectors.

Founded in 1999, Versant Ventures is a global healthcare investment firm dedicated to supporting exceptional entrepreneurs building innovative companies. With over $2 billion under management and offices across North America and Europe, the firm invests across all stages of healthcare company development, with a focus on novel therapeutics. Versant's team, with deep investment, operating, and scientific expertise, takes a hands-on approach to company building.

Founded in 1996, Vivo Capital is a global investment firm focused on healthcare. With approximately $5.8 billion in assets under management and investments in over 290 public and private companies worldwide, the firm operates from Palo Alto, California, with additional offices in Asia. Its team comprises 50 multidisciplinary professionals, including physicians, scientists, entrepreneurs, operating executives, and industry experts. Vivo Capital invests across various healthcare sectors such as biotechnology, pharmaceuticals, medical devices, and healthcare services.

Founded in 1995, SOSV is a global venture capital firm headquartered in New Jersey. It focuses on seed-to-growth stage investments in deep tech innovations, primarily in bio-tech/life sciences and hardware/robotics sectors, with a commitment to human and planetary health.

Venrock is a Palo Alto-based venture capital firm founded in 1969 as the venture capital arm of the Rockefeller family. It concentrates on seed and early-stage investments in technology and healthcare, with interests spanning information technology, life sciences and related sectors in the United States. The firm has supported a broad portfolio of companies, including Apple, Intel, Illumina, DoubleClick, Athenahealth, Gilead Sciences, Nest, SlideShare and Tudou. Venrock emphasizes long-term partnerships with entrepreneurs, combining hands-on venture support with rigorous data analysis to help startups grow into enduring companies.

Founded in 1849, Pfizer is a global pharmaceutical company dedicated to discovering and developing safe, effective, and affordable medicines. With a broad portfolio across various therapeutic areas, Pfizer focuses on wellness, prevention, treatment, and cures for diseases, including investments in emerging technologies to shape the future of healthcare.

Invus Financial Advisors, LLC is an employee-owned investment firm based in New York, founded in 2006. The firm specializes in private equity investments and manages pooled investment vehicles, including hedge funds and funds of funds. Invus focuses on making direct and indirect investments in special situations, venture capital, and growth equity stages, with an emphasis on smaller companies and opportunistic co-investments. The firm adopts a flexible approach, recognizing the uniqueness of each company and the complexities of business transformation. Invus maintains a long-term commitment to its investments, aligning its incentives with those of its partners. With a history of empowering owner-managers since 1985 and a strong backing from a group of European families, Invus Financial Advisors manages over $4 billion in an evergreen fund and operates additional offices in London, Paris, and Hong Kong.

Alexandria Venture Investments is the strategic venture capital arm of Alexandria Real Estate Equities. Based in Pasadena, California, it provides long-term strategic capital to innovative life sciences and technology companies developing breakthrough therapies, diagnostics, and platforms across biopharma, digital health, agrifoodtech, agtech, and related healthcare fields. Established in 1996, the firm invests across seed, early, and growth stages and leverages its deep industry knowledge, extensive investor networks, and scientific advisory resources to support portfolio companies. The unit also pursues opportunities at the intersection of real estate, life sciences, and technology, reflecting its parent company's sector focus and integrated ecosystem approach. It aims to help entities advance human health by partnering with founders to scale transformative technologies.

Founded in 1986, ARCH Venture Partners is a venture capital firm specializing in investments that bring innovations in life sciences to market. It focuses on companies co-founded by scientists and entrepreneurs, with a strong track record in commercializing technologies from academic research institutions and national laboratories.

Redmile Group, established in 2007, is a private equity firm headquartered in San Francisco with an additional office in New York. The company specializes in healthcare investments, focusing on venture capital opportunities within the sector.

Sofinnova Investments is a venture capital firm founded in 1976 and based in Menlo Park, California, with additional offices in La Jolla, California; Montreal, Quebec; and Tokyo, Japan. It backs early to later-stage startups in life sciences and information technology across the United States and Europe, focusing on West Coast U.S. and developed European markets. In life sciences, the firm pursues clinical-stage pharmaceutical, biotechnology and medical technology companies, including drug discovery platforms and entities addressing diseases with unmet medical needs, covering therapeutic areas such as oncology, respiratory, dermatology, ophthalmology, neurology and women's health. In information technology, it funds product-oriented software, enterprise software, service-provider software, and telecommunications infrastructure. Seed investments in both domains typically range from 0.1 million to 1 million, with initial rounds for technology commonly 3-5 million and life science rounds 5-15 million; total commitments generally span 5-15 million for tech and 15-30 million for life sciences. The firm seeks board seats when leading or co-leading early-stage investments.

Founded in Paris in 1972, Sofinnova Partners is a venture capital firm dedicated to life sciences investments. With over €2 billion under management, the firm actively partners with entrepreneurs from seed to later-stage, focusing on biopharmaceuticals, medical devices, and industrial biotechnology. Sofinnova proactively sources deals, often leading Round A financings, and plays an active role in portfolio companies until exit.

Forbion is a venture capital firm based in Naarden, Netherlands, established in 2006. It specializes in early-stage investments within the life sciences and MedTech sectors, focusing on companies involved in drug development and addressing critical medical needs. The firm has a team of nine investment professionals and has built a strong track record since the late 1990s, with successful investments in various notable companies. Forbion manages assets exceeding €400 million across three active funds and co-manages BioGeneration Ventures, which targets academic spin-outs and seed investments in the Netherlands. The firm continues to play a significant role in advancing innovative healthcare solutions through its strategic investments.

Logos Capital is a hedge fund manager based in San Francisco, founded in 2019, specializing in fundamental biotechnology investments. The firm combines in-house data analytics with scientific and clinical expertise to rigorously evaluate potential therapies and treatment platforms. It uses fundamental and sector-focused equity strategies and applies statistical modeling of clinical data to strengthen diligence and identify compelling opportunities with the aim of delivering uncorrelated returns. By integrating medical, scientific, and statistical perspectives, Logos Capital seeks to deepen its conviction in investment ideas and maintain disciplined risk management.

Polaris Partners is a venture capital firm based in Boston, Massachusetts, with offices in San Francisco. Founded in 1996, it targets investments in technology and life science companies across the United States and Europe, supporting startups from early formation to profitable growth. The firm's healthcare and biotechnology focus encompasses digital health, consumer-centric care delivery, patient-provider solutions, data science and analytics, as well as therapeutics, genomics and other life science platforms. It backs companies across business-to-business and business-to-consumer models, software as a service, healthcare information technology and health tech sectors, partnering with repeat entrepreneurs to build durable, scale-ready businesses.

Deerfield Management is a New York-based investment firm established in 1994 that focuses on healthcare. It operates across investment, information, and philanthropy to support the healthcare ecosystem. The firm provides private and public investments and offers long-term, structured capital to both public and private healthcare companies. Its portfolio spans life sciences, medical devices, diagnostics, digital health, and health services. As an investment adviser, it seeks opportunities in healthcare products and services and aims to accelerate innovation by combining capital with industry insight.

The Column Group is a San Francisco-based venture capital firm focused on biotechnology and life sciences, with emphasis on drug discovery and development. It backs early-stage and seed companies in the United States, aiming to build science-driven businesses capable of delivering multiple product opportunities rather than short-term exits. The firm concentrates on oncology and other disease areas including inflammation, infectious disease, metabolic and cardiovascular disorders, and nervous system conditions, seeking to support platform-based discoveries with potential for significant therapeutic impact.

Founded in 2001 and based in Zug, Switzerland, HBM Healthcare Investments is a venture capital firm focusing on the healthcare sector. It invests globally in mature emerging companies primarily in biotechnology/human medicine, diagnostics, and medical technology sectors.

EcoR1 Capital is a San Francisco-based investment firm focused on biotechnology. It provides advisory and investment services to biotechnology companies, pursuing venture-style opportunities in both private and public markets and supporting therapies with potential patient impact. Founded in 2012, the firm emphasizes scientific innovation and translational research and draws inspiration from the EcoR1 restriction enzyme. As an investment adviser, EcoR1 Capital collaborates with clients and partners in the biotech sector to identify promising treatments and help companies address unmet medical needs.

Atlas Venture is an early-stage venture capital firm based in Cambridge, Massachusetts, specializing in life sciences and biotechnology. It supports the translation of high-impact scientific discoveries into medicines for patients through a seed-led venture creation strategy that identifies and builds scalable companies with strong scientific foundations. The firm combines experienced scientists and career venture capitalists to select compelling opportunities and realize value, emphasizing early-stage investments in life sciences and technology. Atlas Venture also maintains a multi-disciplinary team able to advance startups from concept to clinical development and commercial viability.

Deep Track Capital is a venture capital firm focused on life sciences and biotechnology. Based in Greenwich, Connecticut, it partners with management teams of innovative public and pre-IPO companies, offering capital and strategic support through its network and expertise. The firm aims to lead transactions, form large syndicates, and participate in rounds led by other investors, applying time and resources to help portfolio companies grow.

SR One is the corporate venture capital arm of GlaxoSmithKline, investing globally in early-stage life science companies pursuing innovative science with the potential to significantly improve medical care. Since 1985, SR One has invested about $800 million in more than 180 companies.

Omega Funds is a Boston-based venture capital and private equity firm founded in 2004 that concentrates on early-stage investments in healthcare and biotech across North America and Western Europe, backing companies in life sciences, digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and software-as-a-service.

Founded in 1969, F-Prime Capital is a venture capital firm based in Cambridge, Massachusetts. It invests globally in technology and healthcare sectors, supporting entrepreneurs with its extensive domain expertise and relationships.

Casdin Capital is a New York‑based investment firm founded in 2012 by Eli Casdin. The firm specializes in fundamental research and long‑short equity strategies focused on the life sciences and healthcare sectors, including oncology, digital health, and agtech. In addition to its public‑market fund, Casdin Capital invests in early‑stage to late‑stage private companies within these industries. It operates as a Registered Investment Adviser and, as of October 2020, managed approximately $2.2 billion in assets.

Takeda Ventures is a strategic investment arm of Takeda Pharmaceutical Company Limited, focusing on direct and fund-of-fund investments in healthcare and life sciences sectors. It specializes in seed to mid-stage investments, with a primary focus on therapeutics, regenerative medicines, RNA/DNA modulation, and innovative protein/peptide biologics. The firm invests globally but has a strong presence in the United States, Canada, and Europe.

Founded in 1998, Nextech Invest is a venture capital firm based in Zurich, Switzerland. It specializes in early-stage investments globally in healthcare and life science companies, with a focus on biotechnology, therapeutics, drug discovery, and oncology sectors.

Boxer Capital LLC is a venture capital firm founded in 2005 and based in San Diego, California. As a subsidiary of Tavistock Life Sciences, it specializes in investing in both private and public companies within the biotechnology and life science sectors. Boxer Capital focuses on a wide range of companies involved in the drug development lifecycle, from early stage preclinical discovery assets to late stage clinical and commercial entities. The firm aims to support the growth and advancement of biotechnology innovations through its strategic investments.

IP Group is a London-based corporate firm that provides financial, strategic, and commercial expertise to clients internationally. Founded in 2001, the company focuses on creating value through the commercialisation of intellectual property derived from research-intensive institutions. It manages the end-to-end process of identifying viable IP, developing or partnering to build value, and establishing commercial arrangements that translate scientific advances into practical products and businesses. IP Group combines industry insight and financial experience to support science- and technology-based ventures, offering capital as well as strategic guidance to help companies grow and accelerate the impact of research. Its work spans clean technology, life sciences, and other deep technology sectors, with a track record of backing and developing ventures that aim to deliver tangible societal and economic outcomes.

Mission BioCapital is a life science venture capital firm investing in early-stage companies within the biotechnology sector. Founded in Cambridge, Massachusetts in 2009, the company is known for its experienced leadership team and deep support provided to portfolio companies.

Hercules Capital is a specialty finance company that provides senior secured loans and growth capital to privately held venture capital-backed companies across various stages of development in technology, life sciences, and sustainable and renewable technology industries. With over a decade of experience, Hercules offers innovative financing solutions tailored to each company's capital structure and business objectives.

Founded in 1987, Canaan Partners is a global venture capital firm based in Menlo Park, California. With over $5 billion under management, the firm invests in early-stage technology and healthcare companies worldwide.

BioVenture, established in September 2013, specializes in early-stage venture capital investments in the field of life sciences, focusing on biotechnology, drug discovery, medical devices, and healthcare services companies. With a fund size of 540 million yuan, BioVenture provides capital and post-investment support to innovative companies with high growth potential. Backed by Suzhou Industrial Park and BioBay, BioVenture aims to become one of China's most successful medical and pharmaceutical venture funds by leveraging its industry expertise and resources. The team at BioVenture consists of senior investment professionals with deep knowledge of domestic and foreign markets, aiming to help companies grow rapidly and achieve greater success while delivering considerable returns to fund investors. Through joint venture development cooperation, BioVenture seeks to drive innovation and growth in the medical and pharmaceutical industry.

Sequoia Capital Israel is a venture capital firm that backs startups and growth companies across seed to late-stage rounds, with a focus on Israel. It invests across sectors including fintech, financial services, internet, mobile, technology, and healthcare, spanning banking, payments, advertising, ecommerce, data, security, software, and related enabling tech. Typical commitments range from 100,000 to 1 million in seed, 1 to 10 million in early venture, and 10 to 100 million in growth rounds. The firm is based in Tel Aviv and operates as part of Sequoia Capital's global network.

Founded in 1996, MPM Capital is a global investment firm focused on the healthcare and life sciences sectors. It specializes in early-stage investments, typically ranging from $5 million to $50 million, with a primary focus on biotechnology, oncology, medical technology, and specialty pharma. The firm invests globally, with a concentration in North America, Europe, and Asia-Pacific.

Founded in 2004, Pontifax is a global venture capital firm dedicated to investing in transformative healthcare technologies. With offices in Herzliya, Santa Monica, and London, the firm focuses on early-stage investments in biotechnology projects, precision farming, bio-informatics, and pharmaceutical sectors, with a particular emphasis on Israel.

Third Rock Ventures is a Boston-based venture capital firm that specializes in start-up and early-stage investments in life sciences companies, including biotechnology, pharmaceuticals, medical devices, diagnostics, therapeutics, and related information technology and data applications. Founded in 2007, the firm focuses on transformational ventures in the United States and commonly makes substantial initial investments, often leading rounds and pursuing strategic collaborations with larger pharmaceutical and biotechnology companies. It emphasizes active involvement in its portfolio, sometimes taking key management roles to accelerate development, and seeks to support companies through strategic partnerships, milestones, and scale-up efforts. While headquartered in Boston, it maintains a presence in San Francisco to engage with the broader life sciences ecosystem.

Founded in 2000, Aisling Capital is a New York-based investment firm focusing on mid-market and growth-oriented investments in life sciences, healthcare, and technology companies across the United States and Western Europe. The company aims to support leading global healthcare companies commercializing new products driven by biotechnology advancements.

Established in 1973, Johnson & Johnson Innovation facilitates early-stage innovation through strategic partnerships. It connects potential collaborators with resources to advance transformative science and technology across pharmaceuticals, medical devices, and consumer healthcare sectors.

Merck is a biopharmaceutical company dedicated to discovering, developing, and providing innovative medicines and vaccines. With a focus on various diseases, including cancer, infectious diseases, and vaccines, Merck operates globally, with approximately 47% of its sales generated from the US human health segment.

Founded in 2000, Lux Capital is a venture capital firm based in New York and Silicon Valley. It manages over $5 billion in assets, focusing on seed to growth investments at the intersection of technology and sciences. Lux actively supports entrepreneurs building successful businesses in high-growth sectors such as biochemistry, material science, electronics, infrastructure, aerospace, genomics, synthetic biology, and robotics.

Shenzhen Capital Group Co., Ltd (SCGC) is a venture capital firm founded in 1999 by the Shenzhen Government. The company is dedicated to fostering national industries, developing national brands, and promoting economic transformation through investments in emerging sectors. SCGC primarily targets small to medium enterprises and innovative high-tech companies, focusing on those in various stages of growth, including startups and those undergoing transformation. Its investment portfolio spans industries that align with national policy support, such as information technology, internet services, new media, biopharmaceuticals, new energy, environmental protection, chemical engineering, and high-end equipment manufacturing. With a registered capital of 5.42 billion RMB and significant assets under management, SCGC has established itself as a leader in the venture capital landscape, having invested in numerous companies, many of which have achieved public listings across global capital markets.